Oxford BioMedica (GB:OXB) has released an update.
Oxford Biomedica, a leading cell and gene therapy contract development and manufacturing organisation, has appointed its CEO, Dr. Frank Mathias, as the new Chairman of the Board of Directors of ArcticZymes Technologies ASA. The company continues to leverage its over 25 years of experience in viral vectors to collaborate with top pharmaceutical and biotech firms, enabling the delivery of transformative therapies to patients globally.
For further insights into GB:OXB stock, check out TipRanks’ Stock Analysis page.
